FewerJobs.
All jobs

Director, Portfolio Omnichannel (Lung HCP)

Revolution Medicines - Redwood City, California, United States

Posted May 20, 2026

Benefits

Parental leave
Not verified
Non-birth-parent leave
Not verified
Family-building benefits
  • Fertility benefits: Not verified
  • Adoption assistance: Not verified
  • Surrogacy assistance: Not verified
Mental health support
Not verified
Relocation assistance
Not verified
Childcare support
Not verified
Learning budget
Not verified
Verification
Not verified checked Jun 7, 2026
Salary
$211K-$264K From the posting source checked Jun 20, 2026
401(k) match
Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)
$93,011 U.S. median for this role
Projected growth (BLS Employment Projections)
+5.1% - Faster than average

155% above the BLS role benchmark for marketing aggregate.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function
Marketing From the posting source checked Jun 20, 2026
Seniority
Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type
Not verified
Weekend work
Not verified

Company

Company stage
Late-stage From the posting source checked Jun 20, 2026
Equity
Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter
Not verified
Assessment
Not verified
Deadline
Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, Portfolio Omnichannel (Lung HCP) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This newly created role represents a unique opportunity to shape the future of HCP engagement at Revolution Medicines. The Portfolio Omnichannel Strategy & Operations Team is seeking a forward-thinking, digitally fluent marketing operations leader to drive optimal performance while also delivering high-quality customer experiences across our HCP engagement channels. The Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. This leader will define and socialize the strategy and approach to successfully pull through Lung's portfolio of customer engagement ambitions (aligned to the brand's strategic imperatives, objectives and key measures). In a fast-paced, growth-stage biotech environment, this role serves as the connector between strategy and execution partnering cross-functionally

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.

Apply at revmed.com

Apply link not verified; last-live date unavailable.

What verified means

Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.

Related jobs